Stent therapy for malignant superior vena cava syndrome: should be first line therapy or simple adjunct to radiotherapy.
The goal of this paper is to present our experience with superior vena cava (SVC) stenting, as first line procedure for immediate relief, in patients with malignancy, and its potential influence in the subsequent radiotherapy (XRT). Over a 1-year period, 18 patients with SVC syndrome due to severe stenosis secondary to mediastinal malignancy were referred for stent insertion. A SVC score was used to measure treatment effectiveness. Stent insertion had been successful in 18/18 patients (technical success 100%). All patients experienced symptomatic relief within few hours of the procedure. There were no major complications. In all patients we were able to start radiotherapy (XRT) the next day, after stenting according to our new institutional protocol. All patients were able to comply with the XRT program, perfectly well.


CONCLUSIONS
SVC stenting provides immediate significant relief of the very annoying SVC syndrome symptoms, thus facilitating excellent compliance of all the patients to the subsequently XRT protocols. We strongly recommend SVC stenting as first line procedure, in patients with SVC syndrome due to malignancy prior to radiotherapy.
Chatziioannou
A
A
Department of Radiology, Areteion Hospital, University of Athens, 76 Vas Sofias, Athens, GR 10676, Greece. ahatzi@cc.uoa.gr
Alexopoulos
Th
T
Mourikis
D
D
Dardoufas
K
K
Katsenis
K
K
Lazarou
S
S
Koutoulidis
V
V
Ladopoulos
Ch
Ch
Vlachos
L
L
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008479:Mediastinal Neoplasms / Q000150:complications* / Q000532:radiotherapy; D008875:Middle Aged; D011446:Prospective Studies; D015607:Stents; D013479:Superior Vena Cava Syndrome / Q000209:etiology / Q000628:therapy*; D016896:Treatment Outcome